Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be ...

Discover why biotech stock ARVN, trading at a 70% discount to cash value, offers potential upside despite setbacks.

There's been a notable change in appetite for Arvinas, Inc. (NASDAQ:ARVN) shares in the week since its first-quarter report, with the stock down 15% to US$7.72. Revenues of 351% beat expectations by ...

Fintel reports that on May 5, 2025, Truist Securities downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Buy to Hold.

Arvinas (NASDAQ:ARVN) stock drops 33% after announcing workforce cuts and trial removals, despite beating earnings expectations. Read more here.

New Haven-based Arvinas will lay off 131 employees, with 92 in Connecticut, as part of a major workforce reduction.

Ratings for Arvinas ARVN were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings ...

Fintel reports that on May 2, 2025, Jefferies downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Buy to Hold. Analyst Price Forecast Suggests 238.05% Upside As of April 24, 2025, the average ...

Shares of Arvinas stock opened at $7.72 on Friday. The firm has a market capitalization of $563.49 million, a PE ratio of -2.79 and a beta of 2.21. The firm’s 50 day moving average is $9.66 and ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data. Arvinas disclosed the rethink alongside news that it is laying off ...

Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. The business’s quarterly revenue was up 646.2% compared to the same quarter last year.

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuro ...